{"id":993718,"date":"2026-08-11T16:03:36","date_gmt":"2026-08-11T20:03:36","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/taysha-gene-therapies-reports-second-quarter-2026-financial-results-and-provides-corporate-update\/"},"modified":"2026-08-11T16:03:36","modified_gmt":"2026-08-11T20:03:36","slug":"taysha-gene-therapies-reports-second-quarter-2026-financial-results-and-provides-corporate-update","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/taysha-gene-therapies-reports-second-quarter-2026-financial-results-and-provides-corporate-update\/","title":{"rendered":"Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update"},"content":{"rendered":"
\n

\n Completed dosing in the REVEAL pivotal (N=17) and ASPIRE (N=4) trials evaluating TSHA-102 for Rett syndrome; expect to report topline data from 6<\/em>
\n \u2011<\/em>
\n month interim analysis and FDA feedback on the BLA submission pathway in 1H 2027<\/em>\n <\/p>\n

\n TSHA-102 continues to be generally well tolerated with no severe treatment-related SAEs or DLTs across REVEAL Phase 1\/2, pivotal and ASPIRE trials (N=33) as of the August 2026 data cutoff<\/em>\n <\/p>\n

\n Longer-term REVEAL Part A data demonstrated broad, multi-domain functional gains that deepened through \u226512 months post-TSHA-102, with consistent responses across ages and disease severity<\/em>\n <\/p>\n

\n Advanced TSHA-102 commercial readiness activities, including market access planning initiatives and expansion of strategic partnership with Catalent to support future commercial manufacturing<\/em>\n <\/p>\n

\n Completed $230 million follow-on offering, extending cash runway into 2H 2028 and through potential BLA approval of TSHA-102<\/em>\n <\/p>\n

\n Conference call and webcast today at\u00a04:30 PM ET<\/em>\n <\/p>\n

DALLAS, Aug. 11, 2026 (GLOBE NEWSWIRE) — Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today reported financial results for the second quarter ended June 30, 2026, and provided a corporate update.<\/p>\n

\u201cDuring the second quarter, we continued to execute against our clinical development strategy for TSHA-102 while advancing key commercial and manufacturing readiness initiatives in support of a potential BLA submission,\u201d said Sean P. Nolan, Chairman and Chief Executive Officer of Taysha. \u201cThe completion of dosing in our REVEAL pivotal and ASPIRE trials,\u00a0as well as positive longer-term follow-up data from our REVEAL Phase 1\/2 trials continues to strengthen our conviction in TSHA-102 as a potentially transformative therapy for this devastating disease with high unmet need. In addition, the favorable safety profile observed to date across a broad and diverse patient population supports TSHA-102\u2019s potential to safely deliver durable, meaningful functional benefits.\u201d<\/p>\n

Mr. Nolan continued, \u201cWe are working diligently to advance our commercial readiness activities to support the potential launch of TSHA-102, if approved. Our ongoing market and payer research continues to inform our market access strategy and reinforces TSHA-102\u2019s significant value proposition and reimbursement potential. We have also expanded our partnership with Catalent, establishing a robust commercial supply framework to support the potential launch of TSHA-102 and strong demand we expect following potential FDA approval. Looking ahead, with a strengthened balance sheet, we remain focused on executing our BLA-enabling activities and anticipate reporting topline data from the REVEAL pivotal trial six-month interim analysis and FDA feedback on the BLA submission pathway in the first half of 2027.\u201d<\/p>\n

\n Recent Corporate and TSHA-102 Program Highlights<\/strong>\n <\/p>\n